Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) COO Patrick John Finn sold 2,058 shares of Twist Bioscience stock in a transaction on Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total value of $82,299.42. Following the completion of the sale, the chief operating officer now directly owns 265,460 shares of the company's stock, valued at approximately $10,615,745.40. The trade was a 0.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Patrick John Finn also recently made the following trade(s):
- On Wednesday, April 2nd, Patrick John Finn sold 206 shares of Twist Bioscience stock. The shares were sold at an average price of $38.73, for a total transaction of $7,978.38.
- On Monday, February 3rd, Patrick John Finn sold 2,845 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total value of $140,400.75.
Twist Bioscience Price Performance
Twist Bioscience stock opened at $40.11 on Friday. The stock has a market cap of $2.39 billion, a price-to-earnings ratio of -11.87 and a beta of 2.34. The firm has a 50-day moving average of $39.67 and a two-hundred day moving average of $44.25. Twist Bioscience Co. has a 1 year low of $30.32 and a 1 year high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business's revenue for the quarter was up 24.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.75) earnings per share. On average, research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.
Institutional Investors Weigh In On Twist Bioscience
A number of institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc lifted its position in shares of Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after buying an additional 580 shares during the last quarter. Van ECK Associates Corp raised its stake in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after acquiring an additional 267 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience during the third quarter valued at approximately $34,000. Finally, Banque Transatlantique SA acquired a new stake in Twist Bioscience in the fourth quarter valued at approximately $43,000.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Guggenheim set a $50.00 target price on shares of Twist Bioscience in a report on Friday, March 28th. Barclays dropped their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $52.80.
View Our Latest Analysis on Twist Bioscience
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
